A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
ConclusionsFor patients with multiple myeloma, treatment with RUX and MP is effective and well tolerated, and LEN can be used to extend the benefit of this RUX-based treatment.Clinical Trial RegistrationThis study is registered with ClinicalTrials.gov, NCT03110822, and is ongoing. (Source: Targeted Oncology)
Source: Targeted Oncology - April 20, 2024 Category: Cancer & Oncology Source Type: research
Daratumumab ‑resistant multiple myeloma with extramedullary disease successfully treated with combination elotuzumab, pomalidomide and dexamethasone: A case report
Oncol Lett. 2024 Apr 3;27(6):248. doi: 10.3892/ol.2024.14381. eCollection 2024 Jun.ABSTRACTDespite the emergence of monoclonal antibodies, the prognosis of patients with multiple myeloma (MM) with extramedullary disease remains poor. The present report describes a rare case of daratumumab-refractory MM that was successfully treated with elotuzumab, pomalidomide and dexamethasone. A 66-year-old male patient diagnosed with MM was treated with bortezomib, lenalidomide and dexamethasone, followed by high-dose chemotherapy and autologous stem cell transplantation. Thereafter, the patient was treated with lenalidomide and dexame...
Source: Oncology Letters - April 19, 2024 Category: Cancer & Oncology Authors: Masataka Sakashita Naohi Sahara Jun Aoki Takashi Matsunaga Seiichiro Kobayashi Shinsuke Kitahara Tomoki Fujii Nobuhiro Ohno Source Type: research
Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome
Lenalidomide is an immunomodulatory therapy used to treat multiple hematologic malignancies. The incidence of eosinophilia and hypereosinophilia during lenalidomide therapy, and the requirement for high-dose steroids are not well-defined (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 18, 2024 Category: Hematology Authors: Koji Sasaki, Hagop Kantarjian, Guillermo Montalban-Bravo, Danielle Hammond, Elias Jabbour, Rashmi Kanagal-Shamanna, Kelly Chien, Guillermo Garcia-Manero Tags: Original Study Source Type: research
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece
CONCLUSION: In this real-world Len-exposed cohort, Len-refractory patients receiving 1L Len experienced poorer survival outcomes than non-Len-refractory patients, highlighting the unmet need in this patient population which has driven the development of novel therapies.PMID:38616479 | DOI:10.1016/j.clml.2024.03.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 15, 2024 Category: Cancer & Oncology Authors: Efstathios Kastritis Ioannis Ntanasis-Stathopoulos Foteini Theodorakakou Magdalini Migkou Maria Roussou Panagiotis Malandrakis Nikolaos Kanellias Evangelos Eleutherakis-Papaiakovou Despina Fotiou Vassiliki Spiliopoulou Maria Gavriatopoulou Sachin Patel Is Source Type: research
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece
CONCLUSION: In this real-world Len-exposed cohort, Len-refractory patients receiving 1L Len experienced poorer survival outcomes than non-Len-refractory patients, highlighting the unmet need in this patient population which has driven the development of novel therapies.PMID:38616479 | DOI:10.1016/j.clml.2024.03.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 15, 2024 Category: Cancer & Oncology Authors: Efstathios Kastritis Ioannis Ntanasis-Stathopoulos Foteini Theodorakakou Magdalini Migkou Maria Roussou Panagiotis Malandrakis Nikolaos Kanellias Evangelos Eleutherakis-Papaiakovou Despina Fotiou Vassiliki Spiliopoulou Maria Gavriatopoulou Sachin Patel Is Source Type: research
SuFEx-based chemical diversification for the systematic discovery of CRBN molecular glues
Bioorg Med Chem. 2024 Apr 4;104:117699. doi: 10.1016/j.bmc.2024.117699. Online ahead of print.ABSTRACTMolecular glues are small molecules that stabilize protein-protein interactions, enabling new molecular pharmacologies, such as targeted protein degradation. They offer advantages over proteolysis targeting chimeras (PROTACs), which present challenges associated with the size and properties of heterobifunctional constructions, but glues lack the rational design principles analogous to PROTACs. One notable exception is the ability to alter the structure of Cereblon (CRBN)-based molecular glues and redirect their activity to...
Source: Bioorganic and Medicinal Chemistry - April 12, 2024 Category: Chemistry Authors: Trever R Carter Natalia Milosevich Lucas Dada James B Shaum K Barry Sharpless Seiya Kitamura Michael A Erb Source Type: research
Small intestinal angiodysplasia and hemorrhage associated with acquired von Willebrand syndrome type 2A secondary to multiple myeloma: Reversal after treatment with IRD regimen (a case report and a brief review of the literature)
Acquired von Willebrand syndrome (AVWS) is a rare acquired hemorrhagic disorder, characterized by qualitative or quantitative deficiencies in von Willebrand factor (VWF), which is easily misdiagnosed as a genetic von Willebrand disease (VWD) and probably underdiagnosed [1,2]. Usually, the diagnosis of AVWS is complicated, and both clinical and case history evaluation as well as laboratory results are required for discerning AVWS from inherited VWD [2,3]. Here we report a case of AVWS secondary to IgA-kappa type of multiple myeloma (MM), found that the existence of anti-VWF autoantibodies (IgG type) in plasma may contribute...
Source: Thrombosis Research - April 11, 2024 Category: Hematology Authors: Yuxin Zhang, Xuquan Zhou, Yujie Guo, Yongning Gao, Zhiyun Niu, Yi Wu, Yan Wang, Jingyu Zhang Tags: Letter to the Editors-in-Chief Source Type: research
Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with < em > DDX41 < /em > mutations
In this study, we evaluated the efficacy of venetoclax and azacitidine combination therapy in eight consecutive MDS patients with DDX41 mutations at our centre from March 2021 to November 2023. We retrospectively analyzed the genetic features and clinical characteristics of these patients. Our findings suggest that MDS patients with DDX41 mutation may benefit from the therapy, for six subjects received this regimen as initial therapy and five of the six subjects achieved complete remission.PMID:38597818 | DOI:10.1080/16078454.2024.2338509 (Source: Hematology)
Source: Hematology - April 10, 2024 Category: Hematology Authors: Xin Wang Zhijian Xiao Tiejun Qin Zefeng Xu Yujiao Jia Shiqiang Qu Bing Li Lijuan Pan Qingyan Gao Meng Jiao Robert Peter Gale Source Type: research
Ex vivo expansion and activation of V γ9Vδ2 T cells by CELMoDs in combination with zoledronic acid
Int J Hematol. 2024 Apr 6. doi: 10.1007/s12185-024-03763-7. Online ahead of print.ABSTRACTAs multiple myeloma (MM) progresses, immune effector cells decrease in number and function and become exhausted. This remains an insurmountable clinical issue that must be addressed by development of novel modalities to revitalize anti-MM immunity. Human Vγ9Vδ2 T (Vδ2+ γδ T) cells serve as the first line of defense against pathogens as well as tumors and can be expanded ex vivo from peripheral blood mononuclear cells (PBMCs) upon treatment with amino-bisphosphonates in combination with IL-2. Here, we demonstrated that next-genera...
Source: International Journal of Hematology - April 6, 2024 Category: Hematology Authors: Yusuke Inoue Asuka Oda Yusaku Maeda Ryohei Sumitani Masahiro Oura Kimiko Sogabe Tomoko Maruhashi Mamiko Takahashi Shiro Fujii Shingen Nakamura Hirokazu Miki Masahiro Hiasa Jumpei Teramachi Takeshi Harada Masahiro Abe Source Type: research
Ex vivo expansion and activation of V γ9Vδ2 T cells by CELMoDs in combination with zoledronic acid
Int J Hematol. 2024 Apr 6. doi: 10.1007/s12185-024-03763-7. Online ahead of print.ABSTRACTAs multiple myeloma (MM) progresses, immune effector cells decrease in number and function and become exhausted. This remains an insurmountable clinical issue that must be addressed by development of novel modalities to revitalize anti-MM immunity. Human Vγ9Vδ2 T (Vδ2+ γδ T) cells serve as the first line of defense against pathogens as well as tumors and can be expanded ex vivo from peripheral blood mononuclear cells (PBMCs) upon treatment with amino-bisphosphonates in combination with IL-2. Here, we demonstrated that next-genera...
Source: International Journal of Hematology - April 6, 2024 Category: Hematology Authors: Yusuke Inoue Asuka Oda Yusaku Maeda Ryohei Sumitani Masahiro Oura Kimiko Sogabe Tomoko Maruhashi Mamiko Takahashi Shiro Fujii Shingen Nakamura Hirokazu Miki Masahiro Hiasa Jumpei Teramachi Takeshi Harada Masahiro Abe Source Type: research
Ex vivo expansion and activation of V γ9Vδ2 T cells by CELMoDs in combination with zoledronic acid
Int J Hematol. 2024 Apr 6. doi: 10.1007/s12185-024-03763-7. Online ahead of print.ABSTRACTAs multiple myeloma (MM) progresses, immune effector cells decrease in number and function and become exhausted. This remains an insurmountable clinical issue that must be addressed by development of novel modalities to revitalize anti-MM immunity. Human Vγ9Vδ2 T (Vδ2+ γδ T) cells serve as the first line of defense against pathogens as well as tumors and can be expanded ex vivo from peripheral blood mononuclear cells (PBMCs) upon treatment with amino-bisphosphonates in combination with IL-2. Here, we demonstrated that next-genera...
Source: International Journal of Hematology - April 6, 2024 Category: Hematology Authors: Yusuke Inoue Asuka Oda Yusaku Maeda Ryohei Sumitani Masahiro Oura Kimiko Sogabe Tomoko Maruhashi Mamiko Takahashi Shiro Fujii Shingen Nakamura Hirokazu Miki Masahiro Hiasa Jumpei Teramachi Takeshi Harada Masahiro Abe Source Type: research
Immunoglobulin G4-related disease and B-cell malignancy due to an IKZF1 gain-of-function variant
CONCLUSION: Heterozygosity for gain-of-function IKZF1 variants underlies autoimmunity/inflammatory diseases, IgG4-RD and B-cell malignancies, the onset of which may occur in adulthood. Clinical and immunological data are similar to those for patients with unexplained IgG4-RD. Patients may therefore benefit from treatments inhibiting pathways displaying IKAROS-mediated overactivity.PMID:38579942 | DOI:10.1016/j.jaci.2024.03.018 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 5, 2024 Category: Cancer & Oncology Authors: Blanca Garc ía-Solís Mar ía Tapia-Torres Ana Garc ía-Soidán Elisa Hern ández-Brito Mar ía Teresa Martínez-Saavedra Jos é M Lorenzo Salazar Sonia Garc ía-Hernández Ana Van Den Rym Karan Mayani Mayani Jos é Vicente Govantes-Rodríguez Adrian Ger Source Type: research
Immunoglobulin G4-related disease and B-cell malignancy due to an IKZF1 gain-of-function variant
CONCLUSION: Heterozygosity for gain-of-function IKZF1 variants underlies autoimmunity/inflammatory diseases, IgG4-RD and B-cell malignancies, the onset of which may occur in adulthood. Clinical and immunological data are similar to those for patients with unexplained IgG4-RD. Patients may therefore benefit from treatments inhibiting pathways displaying IKAROS-mediated overactivity.PMID:38579942 | DOI:10.1016/j.jaci.2024.03.018 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 5, 2024 Category: Cancer & Oncology Authors: Blanca Garc ía-Solís Mar ía Tapia-Torres Ana Garc ía-Soidán Elisa Hern ández-Brito Mar ía Teresa Martínez-Saavedra Jos é M Lorenzo Salazar Sonia Garc ía-Hernández Ana Van Den Rym Karan Mayani Mayani Jos é Vicente Govantes-Rodríguez Adrian Ger Source Type: research
Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma
ConclusionsLenalidomide appears to be a promising therapeutic agent that offers the possibility of a novel combination of chemotherapy free regimen for patients with B-cell non-Hodgkin lymphoma. (Source: Hormones and Cancer)
Source: Hormones and Cancer - April 5, 2024 Category: Cancer & Oncology Source Type: research
